Trial reportPloS one2013
Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.Frontiers in psychiatry · 2023Pooled it
- A systematic review of neuroimaging and acute cannabis exposure in age-of-risk for psychosis.Translational psychiatry · 2021Pooled it
- Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Intoxication due to Δ9-tetrahydrocannabinol is characterized by disrupted prefrontal cortex activity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- ΔNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Genetic pleiotropy differentially linking brain variation to cannabis use and cannabis use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- The effects of cannabis on mind-wandering.Heliyon · 2025Article
- Development and initial validation of the cannabis-related psychosis risk literacy scale (CPRL): a multinational psychometric study.BMC psychiatry · 2024Article
- Exploring the Link Between Attention-Deficit Hyperactivity Disorder and Cannabis Use Disorders: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2023Review
- Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review.Brain sciences · 2023Review
- The altered state of consciousness induced by Δ9-THC.Consciousness and cognition · 2022Article
- The role of sex in the association between cannabis use and working memory-related brain activity.Journal of neuroscience research · 2022Article
- Cannabinoids, reward processing, and psychosis.Psychopharmacology · 2022Review
- A scoping review of the use of cannabidiol in psychiatric disorders.Psychiatry research · 2022Article
- Cannabis Use and Resting State Functional Connectivity in the Aging Brain.Frontiers in aging neuroscience · 2022Article
- The why behind the high: determinants of neurocognition during acute cannabis exposure.Nature reviews. Neuroscience · 2021Review
- Altered cerebellar-cortical resting-state functional connectivity in cannabis users.Journal of psychopharmacology (Oxford, England) · 2021Article
- Altered resting-state networks may explain the executive impairment in young health immigrants into high-altitude area.Brain imaging and behavior · 2021Article
- Resting state functional connectivity in the default mode network: Relationships between cannabis use, gender, and cognition in adolescents and young adults.NeuroImage. Clinical · 2021Article
- ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders.Journal of attention disorders · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence is increasing for involvement of the endocannabinoid system in cognitive functions including attention and executive function, as well as in psychiatric disorders characterized by cognitive deficits, such as schizophrenia. Executive function appears to be associated with both modulation of active networks and inhibition of activity in the default mode network. In the present study, we examined the role of the endocannabinoid system in executive function, focusing on both the associated brain network and the default mode network. A pharmacological functional magnetic resonance imaging (fMRI) study was conducted with a placebo-controlled, cross-over design, investigating effects of the endocannabinoid agonist Δ9-tetrahydrocannabinol (THC) on executive function in 20 healthy volunteers, using a continuous performance task with identical pairs. Task performance was impaired after THC administration, reflected in both an increase in false alarms and a reduction in detected targets. This was associated with reduced deactivation in a set of brain regions linked to the default mode network, including posterior cingulate cortex and angular gyrus. Less deactivation was significantly correlated with lower performance after THC. Regions that were activated by the continuous performance task, notably bilateral prefrontal and parietal cortex, did not show effects of THC. These findings suggest an important role for the endocannabinoid system in both default mode modulation and executive function. This may be relevant for psychiatric disorders associated with executive function deficits, such as schizophrenia and ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.